The main trial findings
retatrutide results from weight, sugar, and liver trials
The averages were large. Here is what changed, how long it took, and why no average can promise your result.
What do the retatrutide results mean?
Separate trials tracked body weight, average blood sugar, liver fat, and unwanted effects. In the largest weight group, people lost 24.2% of starting weight by week 48 [1], while adults with type 2 diabetes had a 2.02-percentage-point fall on the average-sugar blood test by week 24. That was a large group change on a test that shows sugar over about three months. Their weight fell 16.94% by week 36 [2].
In a smaller fatty-liver study, liver fat fell 82.4% by week 24 [5]. These averages came from groups watched closely by trial staff. Your own weight change may differ, and the trials do not tell what happens years later.
Retatrutide remains under study. No one yet knows how well the changes last after stopping or what harm may appear later. The full account of lasting benefit and harm is also unknown. Larger trials aim to fill those gaps.
Why do weight and blood sugar use different dates?
The weight trial followed 338 adults for its main 48-week result. At week 48, the 12 mg group lost 24.2% of starting weight on average. The placebo group lost 2.1% [1]. Higher study amounts brought more weight loss, more stomach trouble, and a greater rise in resting pulse [1].
The type 2 diabetes trial included 281 adults. The average-sugar blood test fell 2.02 points at 24 weeks in the 12 mg group, against 0.01 points with placebo. At week 36, weight fell 16.94%, against 3.00% with placebo [2]. Blood sugar and weight were checked on different dates, so they answer different questions.
A placebo is a similar-looking shot without retatrutide. It helps separate a drug effect from change caused by simply joining a trial. Researchers can then compare the two group averages. Even so, the average can't foretell your own result.
What happened to liver fat?
The fatty-liver study included people who began with at least 10% liver fat on an MRI-PDFF scan, a special scan that counts liver fat without removing liver tissue from the body. By week 24, liver fat fell 42.9%, 57.0%, 81.4%, and 82.4% across the 1, 4, 8, and 12 mg groups. It rose 0.3% with placebo [5]. In the 12 mg group, 86% got below 5%. The average drop was 86.0% at week 48 [5].
The scan shows how much fat is in the liver. It isn't the same as a biopsy, which checks liver tissue for harm and scars [8]. Reviews that combined several drugs found lower blood-test signs of liver harm and better estimates of scarring [12][13]. Those reviews can't replace a biopsy trial of retatrutide itself.
The liver-fat change is still useful. It tells you what happened on the scans of this study group. It doesn't prove that deep liver scars healed. That harder question hasn't been answered.
Why might your result be different?
An average pulls many different results into one number. Some people change more, some less, and some leave because of side effects [1]. The same limit applies to the 86% liver-fat figure. It describes one study group, not your likely result [5].
The scale also can't tell fat from muscle. One added study found that muscle and other tissue fell along with fat [16]. That doesn't cancel the weight result, but it changes what the loss means.
People who miss visits or leave a trial still matter. If someone quits after a bad side effect, that belongs beside the success number. A useful result keeps the good change and the cost in view. It also keeps the study length attached.
Is retatrutide fda approved after the early trials?
No. A Phase 3 program of large late trials is still testing retatrutide [6][9]. The small Phase 1b trial and mid-stage Phase 2 results are earlier steps. They aren't an approval, an approved use, or a doctor's drug label.
These papers can't give an approval date. Larger trials may back up, narrow, or change the early findings. Government review is separate from publishing a study. For now, retatrutide remains an unapproved study drug.
when will retatrutide be available for doctors?
The research gives no firm date. Phase 3 work means large late trials are still going on, including one on long-term kidney disease [9]. Finishing a trial doesn't mean a government review has begun or ended. Giving a date today would be a guess, not a finding.
retatrutide availability
Retatrutide availability is limited to controlled research in the papers reviewed here. There is no approved drug form, doctor's label, or consumer product [6]. Online listings don't prove a vial holds retatrutide or is clean enough to inject. A printed label can't tie an unknown vial to the results from a known trial drug.
retatrutide cost
No approved product means there is no approved retatrutide price to report. A price for an unchecked vial tells you nothing about its contents. This site does not list sellers, prices, codes, or ways to get the drug. It covers the research, not shopping.
If a product is approved one day, cost will involve insurance, list price, the time on treatment, and health results. None of that is settled here. A firm price now would only be a guess. It might also make an unknown vial look more trustworthy than it is.
What belongs beside every result?
Keep the number with the people studied, the time it took, the placebo result, and the side effects.